KalVista Pharmaceuticals (NASDAQ:KALV) Posts Earnings Results, Misses Estimates By $0.03 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) announced its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.03), Zacks reports.

KalVista Pharmaceuticals Stock Up 5.4 %

KALV opened at $12.64 on Wednesday. The firm has a market capitalization of $624.64 million, a P/E ratio of -3.47 and a beta of 0.76. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $15.50. The stock has a fifty day moving average of $9.53 and a 200-day moving average of $10.27.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KALV. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective on the stock. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities began coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.80.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,669 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at $3,445,097.67. This trade represents a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares in the company, valued at $985,279.88. The trade was a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders purchased 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. Insiders own 10.50% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).